Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma A meta-analysis

doi:10.1097/MD.0000000000022435

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24307

請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24307

題名:	Treatment of chronic hepatitis C regiments containing with recombinant interferon in patients with sustained virological response predicts risk of hepatocellular carcinoma A meta-analysis
作者:	Li, CF;Tsao, SM;Liao, HH;Chen, SC;Lee, YT
關鍵詞:	chronic hepatitis C;direct-acting antiviral agents;hepatitis C virus infection;hepatocellular arcinoma;peg-interferon;ribavirin;sustained virological response
日期:	2020
上傳時間:	2022-08-09T08:00:09Z (UTC)
出版者:	LIPPINCOTT WILLIAMS & WILKINS
ISSN:	0025-7974
摘要:	Given that evidence supporting chronic hepatitis C (CHC) infection developed chance for hepatocellular carcinoma (HCC) following antiviral agents therapy is controversial. We conducted a meta-analysis to examine the risk. We evaluated 20 retrospective and prospective cohort studies published up to 31 December 2017 which investigated the association between sustained virological response (SVR) and incidence of HCC patients treated with monotherapy interferon (IFN) or IFN plus ribavirin (RBV) therapy. The primary outcome of the study was the cumulative incidence of HCC. Odds ratio (OR) was used to evaluate the index of effect size for the association between SVR and treatment with IFN alone or IFN/RBV in CHC patients. SVR patients demonstrated a lower incidence of HCC compared to non-SVR patients. Non-SVR patients had greater odds of HCC incidence compared to SVR patients in the treatment of IFN plus RBV (pooled OR = 7.405, 95% CI = 4.689 to 11.694,P < .001). Non-SVR patients had greater odds of HCC incidence compared to SVR patients in the treatment of IFN monotherapy (pooled OR = 4.135, 95% CI = 3.009 to 5.682,P < .001). Lack of SVR to IFN therapy was significantly associated with greater risk of HCC incidence (pooled OR = 5.035, 95% CI = 3.915 to 6.474,P < .001). SVR could be as a predictor of HCC in CHC patients treated with IFN or IFN plus RBV, and have important implications during HCC screening, whereby patients who fail to achieve SVR need to be screened more rigorously.
URI:	http://dx.doi.org/10.1097/MD.0000000000022435 https://www.webofscience.com/wos/woscc/full-record/WOS:000579119300046 https://ir.csmu.edu.tw:8080/handle/310902500/24307
關聯:	MEDICINE ,2020 ,v99 ,issue 40
顯示於類別:	[中山醫學大學研究成果] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	163	檢視/開啟

在CSMUIR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....